GenQual Announces Initial Closing Of Its First Preferred Equity Funding Round
Released on: November 22, 2011, 10:55 am
GenQual announces initial closing of its first preferred equity funding round
November 22, 2011-
GenQual is pleased to announce initial closing of its first preferred equity round.
Financial terms were not disclosed. This inaugural funding round allows GenQual to
pursue proof-of-principle testing for its companion diagnostic approach for IL-6 mAb
and other JAK/STAT inhibitors for autoimmune diseases and oncology indications.
GenQual aims to prospectively identify responders for clinical-stage therapeutics to
improve drug trial response rates and improve chances for drug approval. The round
remains open for further funding.
GenQual Founder and CEO Jonathan Mirich said, “This funding round allows GenQual to
pursue its business development goals to deliver companion diagnostics for very
expensive IL-6 monoclonal antibody treatment for autoimmune disease, chiefly
rheumatoid arthritis, as well as certain oncology indications. It allows us to
extend collaborative agreements for proof-of-principle testing. We are very excited
about the possibilities in this space.”
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology
indications. Our personalized medicine products are designed to facilitate early
disease detection and diagnosis, and to improve treatment approaches at the
molecular level. GenQual is a privately-held corporation based in the Seattle area.
Jonathan Mirich, Founder & CEO
226 S 197 St., Des Moines, WA 98148
Back to previous page
Submit your press release